$HCAC

Hall Chadwick Acquisition Corp 2Q 2026: Net income $1.37M, EPS $0.09— 10-Q Summary

Hall Chadwick Acquisition Corp (HCAC) reported 2Q 2026 net income of $1.37M and EPS of $0.09, with no operating revenue. The company is a blank-check acquisition vehicle focused on industrials, particularly rare earth recycling. It has signed a Business Combination Agreement with REEcycle, targeting a Q4 2026 close.

Original reporting
Published Aug 19, 2026, 9:41 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 11:04 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Hall Chadwick Acquisition Corp 2Q 2026: Net income $1.37M, EPS $0.09— 10-Q Summary — source image
Decision brief

The 30-second read

$HCACNeutralLow
01

Why it matters

The Q2 filing confirms no operating revenue and modest net income from trust investments, indicating the SPAC is still in the pre‑combination phase.

02

Market read

Limited immediate trading relevance; primarily of interest to SPAC investors monitoring merger progress.

03

What to watch

Trust account funds and the pending merger may attract speculative interest beyond the earnings numbers.

Relevance 5/10Novelty 4/10Timing: post‑market filing on Aug 19, 2026

Background

Hall Chadwick Acquisition Corp is a SPAC focused on industrials and rare‑earth recycling, currently seeking a merger target.

Company-level read

Ticker impact

$HCACNeutralMedium confidence
Context

Q2 2026 10-Q disclosed net income of $1.37M and EPS of $0.09 for Hall Chadwick Acquisition Corp, a blank‑check vehicle.

Expected impact

Limited price movement expected; investors may view the modest profit as a baseline but unlikely to trigger significant trading.

Evidence & confidence

The filing provides the first public numbers for the quarter, but the scale is trivial and the company has no operating business.

Market effects

Provides a data point for the SPAC/blank‑check sector but no broader industry impact.

US micro‑cap market; negligible regional effect.

None

Counterpoint

Despite modest earnings, the upcoming business combination with REEcycle could unlock value if the deal closes.

Key entities

  • Hall Chadwick Acquisition Corp

    Blank‑check acquisition vehicle (ticker HCAC).

  • REEcycle

    Proposed merger partner for Hall Chadwick Acquisition Corp.

Related articles

$IQMed

Form Video Industry Growth Logic Transformation in the AI Era

iQIYI reported Q2 2026 revenue of RMB 6.29 billion, with membership and advertising services contributing RMB 4.01 billion and RMB 1.25 billion, respectively. Non-GAAP operating loss narrowed. Key highlights include positive operating cash flow, 56% YoY growth in content distribution revenue, AI business progress, and 40% YoY growth in overseas membership revenue. The company is undergoing strategic transformation, focusing on AI and decentralization.

$SPGMedAI 8/10

Why Simon Property Group’s malls are attracting more retailers

Simon Property Group reported strong Q2 results with revenue up 20% to $1.79B. CEO Eli Simon noted high retailer demand, 1,200 leases signed, and 17% positive rent spreads. Portfolio occupancy remained at 96%, with re-leased Saks Off 5th space expected to yield higher rents. FFO was flat at $1.185B, while net income decreased 13.1% to $483.1M. Sales productivity rose 14% to $838 per sq ft.

$GILDHighAI 8/10

Gilead’s Core Business Is Accelerating, But Will Its $11 Billion Pipeline Bet Pay Off?

Gilead Sciences (GILD) reported Q2 2026 with double-digit growth in commercial portfolio sales, but posted a significant loss due to $11.2B in R&D expenses from acquisitions. HIV sales rose 12% to $5.7B, while non-HIV areas like liver disease and cancer treatments also showed growth. The company raised its 2026 sales guidance and made strategic acquisitions, but faces risks from clinical development and financial obligations.

$ABBVMedAI 8/10

AbbVie’s Humira Replacement Strategy Is Working, But Could Growth Be Too Concentrated?

AbbVie (NYSE:ABBV) reported Q2 2026 revenue of $16.99B, up 10.2%, driven by immunology and neuroscience. Skyrizi and Rinvoq revenues grew 24.4% and 24.5% respectively, offsetting Humira's 35.9% decline. However, concentration risk exists as these two products made up 47% of revenue. Oncology and aesthetics showed weaker performance, with oncology revenue down 1.5%. Adjusted EPS rose 22.9% to $3.65.